Holmusk opens new office in Basel
Holmusk has opened an office in Basel. The company from Singapore develops digital therapies on the basis of data analysis. Holmusk has placed a focus on the treatment of mental illnesses.
Nawal Roy, CEO of Holmusk (img: Holmusk)
Holmusk has recently moved into a new location at the Novartis Campus of the Switzerland Innovation Park Basel Area. The life sciences company develops data-driven digital therapies to treat a variety of disorders. Its focus is on mental and neurological illnesses, additionally Holmusk is active in the areas of cardiovascular and renal diseases, as well as diabetes.
The new office in Basel represents Holmusk’s seventh international office and second in Europe. According to Stefan Suter, Head of Holmusk Europe, staffing was a key consideration in the choice of Basel as a location: “In Basel we find multilingual, specialized talent from fresh graduates to seasoned professionals to be part of the data-driven revolution in healthcare”. In addition to current and future employees, the companies already located in Basel were also a significant pull factor for Holmusk. “Basel, with its large ecosystem of global leaders in life sciences offers multiple partnership opportunities and allows direct access to expand business into Germany or France”, explains Nawal Roy, CEO of Holmusk.
Holmusk is planning to build the world’s largest platform for what is known as real-world evidence (RWE), in which data from clinical practice is used to develop treatments. Holmusk has already been active in this area for five years, while the company also managed to successfully raise a total of 21.5 million US dollars in 2020 as part of a Series A financing round.
Switzerland Innovation Park Basel Area is operated by Basel Area Business & Innovation. The investment and innovation promotion agency also supported Holmusk during the process of establishing its business in the region.
Share this article
You may also be interested in
A new innovation campus is currently under construction in Allschwil. This will be known as Switzerland Innovation Park Basel Area...Read More
Ysios Capital joins the existing consortium of European investors to expand the Series A financing for Synendos Therapeutics. The Allschwil-based...Read More
Leading Swiss experts in immunology and virology have joined forces in the Basel-based startup RocketVax with the aim of developing...Read More
The Basel-based firm MTIP AG specializes in investments in HealthTech companies. A total of 130 million euros has already been...Read More